Press Releases

Media Contact

Natalie Wildenradt

HotSpot Therapeutics Presents Preclinical Data for Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma

BOSTON, Mass., Jun. 20, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...

HotSpot Therapeutics to Present Additional Preclinical Data on Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma

BOSTON, Mass., May 20, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...

HotSpot Therapeutics Presents Preclinical Data for Potential First-in-Class MALT1 Scaffolding Inhibitor at 65th ASH Annual Meeting

BOSTON, Mass., Dec. 11, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...

HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at 2023 Society for Immunotherapy of Cancer Annual Meeting

BOSTON, Mass., Nov. 3, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...

HotSpot Therapeutics to Introduce First-in-Class MALT1 Scaffolding Inhibitor at 65th ASH Annual Meeting

BOSTON, Mass., Nov. 2, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...

HotSpot Therapeutics to Present Preclinical Data from CBL-B Program at 2023 Society for Immunotherapy of Cancer Annual Meeting

BOSTON, Mass., Sep. 27, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...

HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at AACR Annual Meeting 2023

Preclinical data highlighted ability of HotSpot’s CBL-B inhibitors to enhance the effector function and proliferation of natural killer cells, which...

HotSpot Therapeutics Achieves First-In-Human Dosing with HST-1011, An Investigational Oral Small Molecule Allosteric Inhibitor of CBL-B

  Phase 1/2 study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical activity of HST-1011 dosed as...

HotSpot Therapeutics to Present Two Poster Presentations on CBL-B Program at AACR Annual Meeting 2023

BOSTON, Mass.,  Mar. 14, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...

HotSpot Therapeutics Announces FDA Clearance of IND Application for HST-1011, An Investigational Small Molecule Allosteric Inhibitor of CBL-B

BOSTON, Mass., January 03, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...

AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline

NORTH CHICAGO, Ill. and BOSTON, Mass., December 06, 2022 – AbbVie (NYSE: ABBV) and HotSpot Therapeutics, Inc., a biotechnology company...

HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at 2022 Society for Immunotherapy of Cancer Annual Meeting

BOSTON, Mass., November 10, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of orally delivered,...

HotSpot Therapeutics to Present Preclinical Data from CBL-B Program at 2022 Society for Immunotherapy of Cancer Annual Meeting

BOSTON, Mass., October 5, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...

HotSpot Therapeutics Appoints Paul Thibodeau, Ph.D., as Chief Business Officer

BOSTON, Mass., July 25, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule...

HotSpot Therapeutics Appoints Jose Carmona to Board of Directors

BOSTON, Mass., July 19, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule...

HotSpot Therapeutics Presents Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022

BOSTON, Mass., Apr. 8, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and...

HotSpot Therapeutics to Present Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022

BOSTON, Mass.,  Mar. 8, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and...

HotSpot Therapeutics to Present at the BMO Biopharma Spotlight Series

BOSTON, Mass., Feb. 17, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and...

HotSpot Therapeutics and Caris Life Sciences Announce Collaboration to Advance Precision Medicine Development for Difficult-to-Drug Therapeutic Targets

BOSTON, Mass.,  Jan. 10, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and...

HotSpot Therapeutics Closes $100M Series C to Advance First-in-Class Allosteric Drug Discovery Platform to the Clinic

Boston, Mass., Nov 29, 2021 — HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-class allosteric...

HotSpot Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference

Boston, Mass., Nov. 16, 2021 — HotSpot Therapeutics, Inc., a biotechnology company pioneering thediscovery and development of first-in-class allosteric therapies...

HotSpot Therapeutics to Present New Data Indicating Successful Targeting of CBL-B at 2021 Society for Immunotherapy of Cancer Annual Meeting

Boston, Mass., Nov. 9, 2021 — HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-class allosteric...

HotSpot Therapeutics to Present at the Solebury Trout/BMO Fall Private Company Showcase

  BOSTON, Mass. (Oct. 11, 2021) – HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric...

HotSpot Therapeutics Appoints Timothy Reilly as Chief Development Officer

BOSTON, Mass. (April 14, 2021) – HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric...

HotSpot Therapeutics Appoints Eva Jack as Chief Operating Officer

BOSTON, Mass. (November 17, 2020) – HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric...

HotSpot Therapeutics Completes $65 Million Series B Financing to Advance Pipeline of Novel Allosteric Medicines

BOSTON, Mass. (May 21, 2020) – HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric...

HotSpot Therapeutics Announces Acquisition of Macroceutics, Inc.

BOSTON, Mass. (August 23, 2019)— HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery of nature’s regulatory sites to advance...

HotSpot Therapeutics Expands Board of Directors and Management Team

CAMBRIDGE, Mass. (October 30th, 2018) – HotSpot Therapeutics, a biotechnology company pioneering the discovery of nature’s regulatory sites to advance...

HotSpot Therapeutics Completes $45 Million Series A Financing to Advance New Approach to Allosteric Drug Discovery

“HotSpot is targeting natural regulatory sites on proteins that evolution has perfected over many millions of years. This allows us...

In the News

AbbVie offers up to $335M for connection with HotSpot’s preclinical small-molecule program

AbbVie has formed a connection with HotSpot Therapeutics, inking a global licensing option deal for the biotech’s preclinical small-molecule allosteric therapy and extending the opportunity for up to $295 million in biobucks.

AbbVie puts up $40M to license a treatment from HotSpot Therapeutics

HotSpot Therapeutics has managed to gain some steam financially in the past few years, as the company wrangled several multi-million dollar raises. But its latest deal not only puts more cash into its pockets, it also connects with a major name in pharma.

HotSpot Therapeutics secures $100M to advance allosteric platform

Boston Neighbors Net $256 Million for Treg and Allosteric Therapies

HotSpot Therapeutics snags $100M series C to bring allosteric meds into the clinic

Cancer-Targeting Biotech Startup HotSpot Therapeutics Raises $100M

Atlas-backed startup raises $100M for protein ‘hotspots’

HotSpot gets hotter with $100M raise to push toward clinic

HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic

SR One fuels HotSpot’s $65M B round to fund allosteric R&D

Hotspot’s $65M series B to propel it into the clinic

Boston’s HotSpot Therapeutics Eyes The Clinic Following $65 Million Series B

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

HotSpot announces $65M Series B, as Nimbus pioneers look to keep up in a crowding field

In the decade since Nimbus Therapeutics built a company around computation and little-known phenomena allosteric regulation, the industry has brimmed with algorithm companies and even a few chasing those same targets. Still, a couple of the old leaders think they can keep an edge.

Getting higher-quality hits out of DNA-encoded libraries

DNA-encoded libraries are quickly surpassing traditional high throughput screens as industry’s first stop for hit generation. Now, developers are taking the technology up a notch to get more tractable hits in the output.

HotSpot acquires DNA-encoded library firm Macroceutics

HotSpot Therapeutics, a biotech firm that launched last year to develop allosteric inhibitors for autoimmune and metabolic diseases, has acquired Macroceutics, a 5-year-old provider of DNA-encoded library screening technologies.

HotSpot Acquires Macroceutics for focused allosteric library

HotSpot is adding a key piece to its allosteric inhibitor platform through the acquisition of DNA-encoded library company Macroceutics: the technology to make chemical libraries tailored to allosteric, rather than active, sites.

Moving beyond the active site: why allostery is newly in fashion

Allosteric pockets on proteins have long been viewed as promising alternatives to active sites for controlling protein function. The problem has been finding them.

Drug hunters explore allostery’s advantages

After decades of focus on proteins’ active sites, a new crop of biotech firms is shifting attention to proteins’ hidden regulatory pockets

HotSpot debuts with $45m to find, drug natural allosteric sites

HotSpot Therapeutics Inc. (Cambridge, Mass.) emerged from stealth on Tuesday with a $45 million series A round co-led by Atlas Venture and Sofinnova Partners. T

HotSpot Therapeutics debuts with $45 million to pursue allosteric inhibitors

HotSpot Therapeutics is debuting with $45 million from Atlas Venture and Sofinnova Partners to explore allosteric inhibitors against tough-to-drug targets.

With $45M, HotSpot Takes Drug Research to New Biological Real Estate

In real estate, location is key. The same holds true in the hunt for new drugs. HotSpot Therapeutics is trying to break new ground in drug discovery by hitting locations on a protein that aren’t the conventional targets of most medicines.

Atlas, Sofinnova Bet $45M on ‘HotSpots’

Atlas Venture and Sofinnova Partners co-lead investment in a couple of Nimbus alumni

Hotspot Therapeutics Turns Up The Heat On Natural Allostery

HotSpot is pioneering a new approach to drugging the allosteric sites that Nature itself uses to control proteins.

Float like a butterfly: agility in biotech

In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around agile organizations.

Allostery: Realizing The Promise

With the discovery of the first allosteric inhibitors for bcr-abl that could offer the first clinical cures for CML, allosteric drug discovery is undergoing a resurgence.